These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Measurement of human venous plasma prostacyclin and metabolites by radioimmunoassay: a reappraisal.
    Author: Forder RA, Carey F.
    Journal: Prostaglandins Leukot Med; 1983 Nov; 12(3):323-46. PubMed ID: 6361783.
    Abstract:
    Two radioimmunoassays, the first specific for 6-oxo-PGF1 alpha and the second for 6-oxo-PGF1 alpha, 13, 14-dihydro-6-oxo-PGF1 alpha, 13,14-dihydro-6, 15-dioxo-PGF1 alpha and 6-oxo-PGE1 are described. These radioimmunoassays were used to measure levels of immunoreactive 6-oxo-PGF1 alpha and alleged metabolites of prostacyclin in human venous plasma. Procedures for the direct measurement and extraction of plasma 6-oxo-PGF1 alpha are described and the limitations to which radioimmunoassay of plasma 6-oxo-PGF1 alpha is exposed are discussed. Direct measurement of plasma immunoreactive 6-oxo-PGF1 alpha gave maximal levels of 6.1 pg ml-1 and 4 pg ml-1 in the first and second radioimmunoassays respectively. The latter value reflected combined levels of less than 2 pg ml-1 of 6-oxo-PGF1 alpha and cross-reacting metabolites in venous blood. Extraction of human plasma gave 88.7 +/- 2.2% recovery (mean +/- S.E.M. n = 5 experiments) of [3H]-6-oxo-PGF1 alpha and 80 - 86% recovery of exogenous 6-oxo-PGF1 alpha as immunoreactive 6-oxo-PGF1 alpha. Basal plasma levels of extractable immunoreactive 6-oxo-PGF1 alpha were less than 2.5 pg ml-1. Prostacyclin incubated in vitro with blood was recovered in plasma as immunoreactive 6-oxo-PGF1 alpha and confirmed that conversion to metabolites that cross-reacted with the second antibody, in particular 6-oxo-PGE1, did not occur under experimental conditions. Extraction of [3H]-6-oxo-PGF1 alpha from acidified plasma with methanol resulted in formation of a prostanoid that had properties consistent with the methylated hemiketal isomer of 6-oxo-PGF1 alpha. Under radioimmunoassay conditions this prostanoid was less immunogenic than native [3H]-6-oxo-PGF1 alpha and [3H]-6-oxo-PGF1 alpha extracted from plasma using methyl formate. The low levels of plasma 6-oxo-PGF1 alpha which we report questions the validity of clinical studies that previously described altered levels of plasma 6-oxo-PGF1 alpha in pathophysiological conditions. These studies which were based upon measurement of plasma 6-oxo-PGF1 alpha by radioimmunoassay and GC/MS should now be re-evaluated. Preliminary results from this study have been reported elsewhere (1, 2).
    [Abstract] [Full Text] [Related] [New Search]